The ADL said there has been a near 300% increase in antisemitic incidents in Chicago over the last year, compared to the year before, adding to the growing fear felt by Jewish families.

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

The Anti-Defamation League (ADL) has released a report claiming that Steam is "rife" with extremist and hateful content, and ...

A report has accused Valve of 'allowing the proliferation of hate' on Steam, including Nazi symbols and other extremist ...

Valve has been accused by the Anti-Defamation League of allowing hateful content to fester on Steam. A report published on ...

Steam has come under fire once again fora report that says it allows hate and extremism to flourish on the platform.The ...

The images the Anti-Defamation League found on Steam Community included references to foreign terrorist groups like ISIS.

BioArctic AB (publ) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Over the last year, the ADL locally has tracked a 300% increase in the number of antisemitic incidents in Chicago.